Last reviewed · How we verify
Valsartan and simvastatin
Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol production in the liver.
Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol production in the liver. Used for Hypertension, Hyperlipidemia.
At a glance
| Generic name | Valsartan and simvastatin |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor antagonist and statin |
| Target | AT1 receptor and HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Valsartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, valsartan causes blood vessels to relax and dilate, reducing blood pressure. Simvastatin, on the other hand, works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing cholesterol production, simvastatin helps to lower LDL (bad) cholesterol levels and reduce the risk of cardiovascular events.
Approved indications
- Hypertension
- Hyperlipidemia
Common side effects
- Cough
- Dizziness
- Headache
- Muscle pain
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin (PHASE3)
- A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects (PHASE1)
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects (PHASE1)
- A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan and simvastatin CI brief — competitive landscape report
- Valsartan and simvastatin updates RSS · CI watch RSS
- Novartis portfolio CI